General Biologicals Corporation (TPEX:4117)
Taiwan · Delayed Price · Currency is TWD 12.15
-0.15 (-1.22%)
Feb 11, 2026, 2:59 PM CST
General Biologicals Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -243.6 | -220.82 | -198.83 | -53.19 | 44.14 | 62.15 |
Depreciation & Amortization | 50.88 | 37.6 | 36.04 | 35.18 | 34.97 | 27.39 |
Other Amortization | 0.29 | 0.43 | 0.64 | 0.74 | 0.76 | 3.52 |
Loss (Gain) From Sale of Assets | - | - | - | 0.38 | -9.85 | -0.58 |
Loss (Gain) From Sale of Investments | -1.61 | -3.05 | -4.89 | -0.44 | 5.82 | -1.41 |
Loss (Gain) on Equity Investments | 0.04 | 0.25 | 6.93 | 1.34 | 0.16 | 3.04 |
Stock-Based Compensation | 14.4 | 10.8 | - | - | - | 21.03 |
Provision & Write-off of Bad Debts | 2.64 | 2.64 | -3.88 | -3.71 | -15.74 | 19.71 |
Other Operating Activities | -11.55 | 3.62 | 16.01 | 16.51 | -5.54 | -13.86 |
Change in Accounts Receivable | -39.71 | -65.02 | 25.81 | -14.91 | 33.32 | -20.04 |
Change in Inventory | 35.32 | 30.93 | 31.24 | -35.47 | -18.48 | -35.45 |
Change in Accounts Payable | 21.67 | 59.52 | -0.79 | -10.01 | -1.63 | -3.87 |
Change in Unearned Revenue | 23.59 | 24.43 | 0.66 | 1.51 | -3.78 | 3.74 |
Change in Other Net Operating Assets | -38.84 | 2.56 | 316.75 | 287.08 | -10.18 | -18.64 |
Operating Cash Flow | -186.47 | -116.11 | 225.68 | 225.01 | 38.97 | 46.74 |
Operating Cash Flow Growth | - | - | 0.30% | 477.34% | -16.62% | - |
Capital Expenditures | -456.47 | -1,545 | -424.02 | -248.42 | -14.73 | -23.26 |
Sale of Property, Plant & Equipment | - | - | - | 2.19 | 1.51 | 1.25 |
Cash Acquisitions | -0.92 | -0.92 | - | - | - | -29.5 |
Sale (Purchase) of Intangibles | -0.42 | -0.85 | -1 | -0.18 | -2.59 | -2.67 |
Investment in Securities | - | - | 88.9 | -29.65 | 59.04 | -126.95 |
Other Investing Activities | -6.8 | -8.24 | -6.19 | -1.84 | -118.98 | -5.17 |
Investing Cash Flow | -464.62 | -1,555 | -342.31 | -277.91 | -75.76 | -186.3 |
Short-Term Debt Issued | - | 150 | 50 | 5 | - | - |
Long-Term Debt Issued | - | 1,718 | 35 | - | 5 | - |
Total Debt Issued | 970.92 | 1,868 | 85 | 5 | 5 | - |
Short-Term Debt Repaid | - | -140 | -5 | - | - | -26 |
Long-Term Debt Repaid | - | -21.99 | -7.63 | -14.74 | -9.26 | -32.21 |
Total Debt Repaid | -361.32 | -161.99 | -12.63 | -14.74 | -9.26 | -58.21 |
Net Debt Issued (Repaid) | 609.6 | 1,706 | 72.37 | -9.74 | -4.26 | -58.21 |
Issuance of Common Stock | - | - | - | - | - | 530 |
Other Financing Activities | 19.04 | - | - | - | - | - |
Financing Cash Flow | 628.64 | 1,706 | 72.37 | -9.74 | -4.26 | 471.8 |
Foreign Exchange Rate Adjustments | 1.54 | -0.07 | -0.81 | 16.05 | -0.79 | -4.17 |
Net Cash Flow | -20.9 | 34.52 | -45.06 | -46.59 | -41.83 | 328.07 |
Free Cash Flow | -642.94 | -1,661 | -198.33 | -23.42 | 24.24 | 23.49 |
Free Cash Flow Growth | - | - | - | - | 3.23% | - |
Free Cash Flow Margin | -255.76% | -659.37% | -74.89% | -6.32% | 4.40% | 4.93% |
Free Cash Flow Per Share | -10.75 | -27.77 | -3.31 | -0.39 | 0.41 | 0.45 |
Cash Interest Paid | 8.59 | 8.46 | 7.14 | 7.32 | 11 | 3.32 |
Cash Income Tax Paid | 0.13 | - | - | - | - | - |
Levered Free Cash Flow | -614.92 | -2,268 | 291.73 | -291.83 | 27.32 | 1.96 |
Unlevered Free Cash Flow | -599.67 | -2,260 | 299.22 | -281.29 | 34.19 | 4.03 |
Change in Working Capital | 2.03 | 52.42 | 373.67 | 228.19 | -15.76 | -74.26 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.